Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis

Zeren Ma1*, Yong Li2, Ming Zhou1, Kedi Huang1, Hejun Hu1, Xiaoping Liu1, Xiaosheng Xu1

1 Spinal and Joint Unit, Department of Orthopedics, Nanchang Hongdu Hospital of Traditional Chinese Medicine, Nanchang, Jiangxi 330006, China, 2 Department of Orthopaedics, Shanxi Province People's Hospital, Xi'an 710068, China

* zerenma_med@sina.com

Abstract

Background
Aim of the present study was to identify the predictors of ibandronate efficacy in subjects with osteoporosis or decreased bone mineral density (BMD).

Method
Several electronic databases were searched by using specific keywords for the acquisition of research articles reporting the efficacy of ibandronate in subjects with osteoporosis or decreased BMD. Metaregression analyses were carried out by using changes in the BMD of lumbar spine and total hip following ibandronate treatment as dependent (outcome) variables against several independent (explanatory) variables.

Results
Data were extracted from 34 studies (11,090 ibandronate treated subjects) which fulfilled eligibility criteria. A history of previous fracture/s was reported by 46% of these subjects. In overall population, longer treatment duration from 1 to 5 years, increasing age, history of previous fractures, lower baseline T score, and higher baseline levels of C-terminal telopeptide of type 1 collagen (CTX) predicted higher ibandronate efficacy in improving BMD of the lumbar spine as well as of the total hip. Lower baseline levels of vitamin D and higher baseline levels of bone specific alkaline phosphatase (BSAP) predicted higher efficacy of ibandronate for lumbar spine only. In postmenopausal women with osteoporosis or decreased BMD, in addition to above-mentioned predictors, better efficacy of ibandronate was also associated with increasing time since menopause for both lumbar spine and total hip and lower body weight for lumbar spine only.

Conclusion
Longer treatment duration from 1 to 5 years, increasing age, lower baseline T scores, and higher serum CTX levels are identified as the predictors of better efficacy of ibandronate in the study subjects with osteoporosis or decreased BMD.
Introduction

Osteoporosis is a disease in which the bone mineral density (BMD) and the quality of bone are reduced that predisposes individuals to a higher risk of low-trauma fractures [1]. Annual incidence of osteoporotic fractures worldwide is estimated at about 9 millions of which 75–80% fractures are sustained by 200 million women suffering from osteoporosis [2]. This poses a significant global public health concern with socioeconomic implications. It is estimated that the incidence of hip fractures will increase up to 240% in women and 310% in men by the year 2050 [3,4].

Osteoporosis cause significant morbidity and mortality in elderly. It can cause kyphosis, restrictive lung disease, abdominal distension, and height loss. Osteoporotic fractures are more common in vertebrae, hip and wrist [5]. Hip fractures are associated with significantly higher mortality rates and most of the patients die within 3–6 months after the event. Among the survivors majority of the patients face significantly compromised performance in their activities of daily living [6–8]. Osteoporotic fracture risk increases with age; whereas 10-year fracture risk at the age of 50 years is 9.8% in women and 7.1% in men, at the age of 80, it is 21.7% in women and 8% in men [9].

Of the multiple therapeutic options available for the management of osteoporosis, bisphosphonates act to reduce osteoclast mediated bone resorption [10,11] by inducing osteoclast suppression and apoptosis [12]. Aminobisphosphonates including alendronate, ibandronate, risedronate and zoledronate are considered more efficacious than non-nitrogenous bisphosphonates. Because of the poor bioaccessibility of orally taken bisphosphonates (less than 1% absorption in the gut) and inadequate patient compliance [13], bisphosphonates may also be infused via the intravenous route which enhances their bioavailability at much lower frequency of administration.

Among the bisphosphonates, ibandronate offers relatively flexible dosing formulations and administration schedule. A number of trials have examined the efficacy of ibandronate in subjects with osteoporosis or decreased BMD [14–58] and majority of these studies found ibandronate significantly efficacious in improving BMD which is also reported by recent meta-analyses [59,60]. Identifying predictors of ibandronate efficacy can help in decision making as multiple options are available for treating osteoporosis which has a multifactorial etiology. We have used data from 34 studies for carrying out meta-regression analyses in order to identify the predictors of ibandronate efficacy in improving BMD of lumbar spine and total hip in subjects with osteoporosis or decreased BMD.

Methods

Literature search strategy

Relevant studies were identified after a comprehensive literature search in multiple electronic databases including EMBASE, Google Scholar, OVID SP, PubMed and Web of Science. The major medical subject headings (MeSH) and keywords were used in different combinations. For primary search, [ibandronate bone mineral density osteoporosis] combination was used. For secondary searches, various combinations including [ibandronate postmenopausal osteoporosis], [ibandronate bone mineral density osteoporosis lumbar spine], [ibandronate bone mineral density osteoporosis hip], [ibandronate bone mineral density postmenopausal osteoporosis (PMO)], [ibandronate osteoporosis fractures], [ibandronate osteoporosis bone resorption], [ibandronate osteoporosis osteocalcin], [ibandronate osteoporosis sclerostin], [ibandronate osteoporosis C-terminal telopeptide of type 1 collagen (CTX)], [ibandronate osteoporosis bone specific alkaline phosphatase (BSAP)], [ibandronate osteoporosis...
procollagen type I N-terminal propeptide (PINP), [ibandronate osteoporosis parathyroid hormone (PTH)], and [ibandronate osteoporosis vitamin D] were used. Same strategy was used for each database. The search encompassed original research papers published before February 2015. Bibliographies of important relevant research articles were manually searched. This study does not involve ethical review.

Inclusion and exclusion criteria
The inclusion criterion was—trials evaluating the efficacy of ibandronate by treating subjects (individuals with osteoporosis or decreased BMD) for one or more years and measured baseline, later stage/s and endpoint BMD of lumbar spine and/or hip. The study/studies was/were excluded if it/these used ibandronate for the purpose other than skeletal improvement; utilized ibandronate in combination with other therapeutic regimens; provided relevant but inadequate information regarding the measures of data spread or the variables of interests; or studied persistence/adherence data only.

Data extraction and statistical analysis
Information on demographic characteristics of the study subjects, osteoporotic condition, trial endpoints, outcomes, and baseline values of related serological markers and other clinical characteristics were extracted from each study report/s and tabulated in Microsoft Excel spreadsheets. The metaregression analyses were stratified first by lumbar spine and total hip BMD for overall population of this study and then by the postmenopausal women with osteoporosis or decreased BMD and non-PMO subjects with osteoporosis or decreased BMD. For each of the dependent variables (percent changes from baseline in the BMD of lumbar spine or total hip), we tested several explanatory (independent) variables including treatment duration, number of ibandronate treated patients, gender, age, weight, height, body mass index (BMI) of the subjects, history of previous fractures, time since menopause, baseline lumbar spine / total hip T scores, and baseline 25-OH vitamin D, PTH, osteocalcin, CTX, PINP, BSAP, calcium, and phosphate levels in the blood. After calculating the percent changes in the BMD of lumbar spine and total hip for each of the included studies, metaregression analyses were carried out with STATA software (Version 12; College station, Texas) under random effects model using restricted maximum likelihood method. A P<0.1 was considered to be significant. Statistical indices for heterogeneity assessment were tau² and I².

Results
Thirty four studies [14–58] including 28 randomized controlled, 1 non-randomized controlled [15], 4 prospective observational [26,30,36,57], and 1 retrospective [50] studies fulfilled eligibility criteria. A flowchart of study screening and selection process is presented in Fig 1. Overall population of this meta-analysis was 11,090 ibandronate treated subjects of which 7,531 were administered ibandronate orally and 3559 intravenously.

Age, height, weight and BMI of the patients as mean and standard deviation were 62.4 ± 7.6 years, 159 ± 6.7 centimeters, 64.7 ± 12 kilograms, and 25.3 ± 4.4 kg/m², respectively. Duration of ibandronate treatment in these trials was 1.9 ± 1.1 (1–5) years. A history of previous fractures was reported by 46% of the study subjects. In postmenopausal women with osteoporosis or decreased BMD, time since menopause was 15.4 ± 7 years. Baseline values of related serum markers were: Vitamin D 25OH (30 ± 12 ng/ml), PTH (50 ± 25 pg/ml), osteocalcin (24 ± 10 ng/ml), CTX (0.4 ± 0.3 ng/ml), PINP (50 ± 31 ng/ml), BSAP (59 ± 20 U/l), calcium (9.4 ± 0.5 mg/dl), and serum phosphate (3.7 ± 0.6 mg/dl).
Based on the statistical significance in the metaregression analyses, several predictors of the efficacy of ibandronate in improving BMD of the lumbar spine in subjects with osteoporosis or decreased BMD (all conditions) were identified. Longer treatment duration from 1 to 5 years, increasing age, lower body weight, history of previous fractures, lower baseline T score of lumbar spine, lower baseline levels of 25-OH vitamin D, and higher baseline levels of serum BSAP and CTX were significantly associated with higher efficacy of ibandronate (Table 1; Figs 2 and 3). On the other hand, number of participants, gender, height, BMI, baseline serum levels of PTH, PINP, osteocalcin, calcium and phosphate did not show any significant relationship with the efficacy of ibandronate in improving lumbar spine BMD in the overall population of this meta-analysis.

The predictors of the efficacy of ibandronate in improving BMD of the total hip in subjects with osteoporosis or decreased BMD (all conditions) were: Treatment duration from 1 to 5 years, increasing age, history of previous fractures, lower baseline T score of total hip, and higher baseline serum CTX (Table 1; Figs 2 and 3). Number of participants, gender, weight, height, BMI, baseline serum levels of 25-OH vitamin D, PTH, PINP, osteocalcin, calcium and phosphate did not show any significant relationship with the efficacy of ibandronate in improving total hip BMD in subjects with osteoporosis or decreased BMD.

In postmenopausal women with osteoporosis or decreased BMD, longer treatment duration (1 to 5 years), increasing age, lower body weight, increasing time since menopause, lower baseline T score of lumbar spine, lower baseline serum levels of 25-OH vitamin D, and higher baseline serum levels of CTX and BSAP predicted better efficacy of ibandronate in improving BMD of the lumbar spine (Table 2). In these women, increasing age, increasing time since
menopause, lower BMI, lower baseline T score of total hip, and higher baseline serum levels of CTX predicted better efficacy of ibandronate in improving BMD of the total hip (Table 2).

In non-PMO study subject with osteoporosis or decreased BMD, longer treatment duration (1–5 years) and history of previous fractures were identified as the predictors of better ibandronate efficacy in improving the BMD of lumbar spine (Table 3). Less data were available for the metaregression analyses of other variables for non-PMO osteoporosis subjects and individuals with decreased BMD.

### Table 1. Predictors of the efficacy of ibandronate in improving BMD in osteoporosis patients.

| Change in lumbar spine BMD | No. of datasets | \( \tau^2 \) | Coefficient [95% CI] | \( P \) |
|----------------------------|----------------|-------------|----------------------|------|
| **Lumbar spine**           |                |             |                      |      |
| Treatment duration          | 50             | 9.22        | 1.086 [0.141, 2.032] | 0.025|
| Number of participants      | 50             | 10.36       | 0.00057 [–0.003, 0.004] | 0.752|
| Gender                      | 50             | 10.29       | 0.0063 [–0.025, 0.038] | 0.683|
| Age                         | 49             | 10.07       | 0.215 [0.101, 0.327] | 0.001|
| Body weight                 | 34             | 5.42        | –0.183 [–0.335, –0.031] | 0.020|
| Body height                 | 30             | 4.903       | 0.0663 [–0.23, 0.249] | 0.958|
| Body mass index             | 35             | 4.77        | –0.353 [–0.907, 0.202] | 0.205|
| History of fractures        | 27             | 4.504       | 0.038 [0.0003, 0.078] | 0.053|
| Baseline T score (lumbar spine) | 50         | 7.886       | –1.432 [–2.296, –0.569] | 0.002|
| Baseline serum vitamin D 25OH | 31           | 3.104       | –0.252 [–0.365, –0.141] | 0.0001|
| Baseline serum PTH          | 16             | 5.245       | –0.027 [–0.068, 0.014] | 0.191|
| Baseline serum osteocalcin  | 21             | 5.04        | –0.089 [–0.245, 0.066] | 0.241|
| Baseline serum BSAP         | 19             | 10.75       | 0.0565 [0.0115, 0.1016] | 0.017|
| Baseline serum CTX          | 23             | 1.924       | 17.947 [11.33, 24.57] | 0.0001|
| Baseline serum PINP         | 5              | 1.454       | –0.0868 [–0.228, 0.091] | 0.264|
| Baseline serum calcium      | 9              | 0.432       | –1.46 [–8.84, 5.964] | 0.656|
| Baseline serum phosphate    | 5              | 5.079       | –2.982 [–12.29, 6.32] | 0.383|
| **Total hip**               |                |             |                      |      |
| Treatment duration          | 32             | 0.718       | 0.274 [–0.028, 0.577] | 0.074|
| Number of participants      | 32             | 0.811       | 0.0004 [–0.0007, 0.0015] | 0.461|
| Gender                      | 32             | 0.702       | –0.0088 [–0.022, 0.004] | 0.163|
| Age                         | 32             | 0.665       | 0.0069 [–0.002, 0.124] | 0.057|
| Body weight                 | 22             | 0.292       | 0.0106 [–0.044, 0.065] | 0.692|
| Body height                 | 22             | 0.289       | –0.0121 [–0.093, 0.069] | 0.759|
| Body mass index             | 24             | 0.598       | –0.1143 [–0.373, 0.144] | 0.370|
| History of fractures        | 18             | 0.68        | 0.0176 [–0.0032, 0.0385] | 0.092|
| Baseline T score (total hip)| 23             | 0.747       | –1.068 [–1.818, –0.319] | 0.007|
| Baseline serum vitamin D 25OH | 22           | 0.781       | –0.422 [–0.120, 0.036] | 0.272|
| Baseline serum PTH          | 10             | 0.968       | 0.0087 [–0.039, 0.057] | 0.689|
| Baseline serum osteocalcin  | 16             | 0.955       | 0.0182 [–0.069, 0.106] | 0.662|
| Baseline serum BSAP         | 14             | 0.917       | 0.0088 [–0.009, 0.027] | 0.309|
| Baseline serum CTX          | 14             | 0.5         | 5.988 [1.483, 10.494] | 0.013|
| Baseline serum PINP         | 4              | 1.09        | –0.159 [–0.499, 0.182] | 0.183|
| Baseline serum calcium      | 7              | 1.314       | –3.266 [–11.32, 4.787] | 0.245|
| Baseline serum phosphate    | 3              | 0           | –9.652 [–55.48, 36.08] | 0.277|

Abbreviations: BSAP, bone specific alkaline phosphatase; CI, confidence interval; CTX, C-terminal telopeptide of type 1 collagen; PINP, procollagen type I N-terminal propeptide; PTH, parathyroid hormone; SE, standard error

doi:10.1371/journal.pone.0150203.t001
In the present metaregression analyses, longer treatment duration from 1 to 5 years, increasing age, lower body weight, lower baseline T score, and higher baseline levels of CTX predicted higher ibandronate efficacy in improving BMD of the lumbar spine as well as of total hip. Lower baseline levels of vitamin D and higher baseline levels of BSAP predicted higher efficacy of ibandronate for lumbar spine only. In postmenopausal subjects with osteoporosis or decreased BMD, in addition to above-mentioned predictors, better efficacy of ibandronate was also associated with increasing time since menopause. There was a significant negative relationship between the baseline age and baseline T score of lumbar spine ($r = -0.55; p < 0.0001$) as well as of total hip ($r = -0.279; p = 0.049$).

### Postmenopausal women with osteoporosis or decreased BMD

In postmenopausal subjects with osteoporosis or decreased BMD, longer treatment duration (from 1 to 5 years) was associated with higher ibandronate efficacy in improving lumbar spine and total hip BMD in the present study. These results support the predictive model of
Mandema et al [61] in which non-linear least squares random effects metaregression analyses were utilized to predict the differences from placebo in percent changes from baseline in BMD at 12, 24, and 36 months after ibandronate and other related therapies.

We have found a significant negative relationship between baseline T-scores of lumbar spine as well as of total hip and the efficacy of ibandronate. Moreover, there was a significant negative relationship between baseline age of the subjects and T scores. This observation suggests that ibandronate treatment is more effective in subjects with more serious conditions of osteoporosis and that ibandronate is useful for long-term use. However, there can be a potential selection bias in the trials’ recruitment phase of the included studies as many other studies have reported a positive relationship between the start of any treatment for osteoporosis and T scores [62–65]. Moreover, diagnosis and treatment rates of osteoporosis are quite low [66,67].

Age is strongly associated with osteoporosis and fracture risk [68–70]. In this study we have found that both with increasing age and increasing time since menopause the efficacy of ibandronate increases in improving BMD of lumbar spine as well as total hip in postmenopausal subjects with osteoporosis or decreased BMD. However, in these subjects, the efficacy of ibandronate in improving BMD of both lumbar spine and total hip was inversely associated with

---

Fig 3. Scatterplots showing the relationships between ibandronate efficacy in terms of percent change in BMD of lumbar spine (a & c) or total hip (b & d) and percent patients with a history of previous fractures (a & b) or baseline serum CTX levels (c & d). See Table 1 for corresponding values.

doi:10.1371/journal.pone.0150203.g003
Table 2. Predictors of the efficacy of ibandronate in improving BMD of the PMO patients and postmenopausal women with decreased BMD.

| Variables                              | Datasets | tau^2   | Coefficient [95% CI]   | P     |
|----------------------------------------|----------|---------|------------------------|-------|
| Lumbar Spine                           |          |         |                        |       |
| Treatment duration                     | 37       | 3.535   | 0.551 [−0.088, 1.189]  | 0.089 |
| Number of participants                 | 37       | 3.579   | 0.002 [−0.0005, 0.004] | 0.122 |
| Age                                    | 37       | 1.882   | 0.329 [0.214, 0.443]   | <0.0001|
| Body weight                            | 27       | 2.213   | −0.294 [−0.470, −0.118] | 0.002 |
| Body height                            | 24       | 1.38    | −0.162 [−0.441, 0.116] | 0.240 |
| Body mass index                        | 27       | 2.006   | −0.019 [−0.557, 0.519] | 0.943 |
| History of fractures                   | 19       | 2.124   | 0.008 [−0.025, 0.042]  | 0.614 |
| Time since menopause                   | 27       | 2.037   | 0.295 [0.190, 0.401]   | <0.0001|
| Baseline T score (lumbar spine)        | 37       | 1.876   | −1.341 [−1.824, −0.858] | <0.0001|
| Baseline serum vitamin D 25OH          | 24       | 2.808   | −0.237 [−0.372, −0.1025] | 0.001 |
| Baseline serum PTH                     | 11       | 6.047   | −0.001 [−0.103, 1.004] | 0.979 |
| Baseline serum osteocalcin             | 19       | 4.992   | −0.113 [−0.276, 0.050] | 0.162 |
| Baseline serum BSAP                    | 14       | 3.025   | 0.037 [0.007, 0.067]   | 0.019 |
| Baseline serum CTX                     | 21       | 2.028   | 17.99 [11.14, 24.84]   | <0.0001|
| Total hip                              |          |         |                        |       |
| Treatment duration                     | 27       | 0.664   | 0.246 [−0.052, 0.546]  | 0.102 |
| Number of participants                 | 27       | 0.730   | 0.0005 [−0.0006, 0.0016] | 0.363 |
| Age                                    | 27       | 0.5147  | 0.129 [0.046, 0.212]   | 0.004 |
| Body weight                            | 19       | 0.259   | −0.069 [−0.217, 0.079] | 0.338 |
| Body height                            | 19       | 0.258   | −0.075 [−0.233, 0.083] | 0.332 |
| Body mass index                        | 20       | 0.4538  | −0.289 [−0.628, 0.049] | 0.089 |
| History of fractures                   | 14       | 0.628   | 0.013 [−0.007, 0.034]  | 0.195 |
| Time since menopause                   | 20       | 0.476   | 0.114 [0.046, 0.018]   | 0.002 |
| Baseline T score (total hip)           | 18       | 0.741   | −0.1852 [−1.686, −0.018] | 0.046 |
| Baseline serum vitamin D 25OH          | 18       | 0.657   | −0.050 [−0.139, 0.038] | 0.245 |
| Baseline serum PTH                     | 8        | 0.451   | 0.0007 [−0.038, 0.04]  | 0.964 |
| Baseline serum osteocalcin             | 15       | 0958    | 0.017 [−0.0718, 0.106] | 0.686 |
| Baseline serum BSAP                    | 12       | 1.067   | 0.009 [−0.01, 0.029]   | 0.319 |
| Baseline serum CTX                     | 13       | 0.5014  | 6.019 [1.462, 10.577]  | 0.014 |

Abbreviations: BSAP, bone specific alkaline phosphatase; CI, confidence interval; CTX, C-terminal telopeptide of type 1 collagen; PINP, procollagen type I N-terminal propeptide; PMO, postmenopausal osteoporosis; PTH, parathyroid hormone; SE, standard error

doi:10.1371/journal.pone.0150203.t002

Table 3. Predictors of the efficacy of ibandronate in improving BMD of lumbar spine in non-PMO patients and individuals with decreased BMD.

| Variables                              | Datasets | tau^2   | Coefficient [95% CI]   | P     |
|----------------------------------------|----------|---------|------------------------|-------|
| Treatment duration                     | 13       | 21.46   | 3.488 [−0.215, 7.192]  | 0.062 |
| Number of participants                 | 13       | 30.01   | 0.0062 [−0.0216, 0.034] | 0.632 |
| Gender                                 | 12       | 27.93   | −0.005 [−0.101, 0.091] | 0.908 |
| Age                                    | 12       | 27.6    | 0.064 [−0.265, 0.394]  | 0.674 |
| Body mass index                        | 8        | 16.48   | 0.116 [−1.907, 2.14]   | 0.893 |
| History of previous fractures          | 8        | 9.59    | 0.096 [−0.017, 0.209]  | 0.083 |
| Baseline T score (lumbar spine)        | 13       | 26.72   | −1.791 [−5.19, 1.61]   | 0.217 |

Abbreviations: BMD, bone mineral density; CI, confidence interval; PMO, postmenopausal osteoporosis

doi:10.1371/journal.pone.0150203.t003
baseline T scores. Thus, it seems plausible that ibandronate efficacy increases as the baseline T-score decreases and that age per se is not a good predictor of ibandronate efficacy.

Osteoclasts degrade type I collagen (one of the most abundant bone constituents) as a result CTX is released in the blood. Bisphosphonate mediated CTX decrease can be quantified as earlier as one week after the start of treatment [71]. In the present study, higher baseline serum CTX levels predicted higher efficacy of ibandronate in improving BMD of both lumbar spine and total hip, and after treatment, this association became negative (r = −0.736; p<0.0001 for lumbar spine and r = −0.5; p = 0.009 for total hip). There was also a significant positive association between age and baseline CTX levels (r = 0.583; p = 0.01) and a significant negative association between the percent change in CTX following ibandronate treatment and age (coefficient: −2.558; p = 0.005). Although, decrease in CTX can promote osteonecrosis of the jaw [69], the risk assessment of CTX mediated osteonecrosis of the jaw bone is controversial [72]. Overall safety profile of ibandronate is good and for some parameters better than that of other aminobisphosphonates [73].

Another finding of the present study is that there was a significant negative relationship between baseline 25-OH vitamin D and the efficacy of ibandronate in improving the BMD of lumbar spine but not of total hip. Moreover, there was a significant positive correlation between baseline vitamin D levels and baseline T score of lumbar spine (r = 0.505; p = 0.019) but not of total hip. Although, inadequate vitamin D levels are reported in individuals with hip fracture but fracture incidence itself can influence vitamin D levels [74–76]. There is evidence to suggest that vitamin D alone is less effective for hip bone strength e.g. in elderly women, one year treatment with calcium and vitamin D prevented hip BMD decrease but the effects were mainly in the women with below median baseline 25-OH vitamin D [77] and a meta-analysis of 53 trials (91,791 subjects) did not find vitamin D supplementation effective in preventing hip fractures [78]. Thus it may be possible that vitamin D have differential effects on lumbar spine and hip bones.

In the present study, lower BMI was a significant predictor of ibandronate treatment in improving total hip BMD in in postmenopausal subjects with osteoporosis or decreased BMD. Additionally, lower body weight was also predicting better ibandronate efficacy in improving lumbar spine BMD in overall population of the present study. Lower BMI is well-reported to be associated with higher fracture risk [79,80].

Non-PMO subjects with osteoporosis or decreased BMD

Relatively less data were available to test explanatory variables against outcome variables in order to evaluate the predictors of ibandronate in improving lumbar spine BMD in non-postmenopausal subjects with osteoporosis or decreased BMD. Longer treatment duration (from 1 to 5 years) and history of previous fractures were positively associated with higher ibandronate efficacy in improving lumbar spine BMD in the present study. Data were inadequate to evaluate the predictors of ibandronate in improving total hip BMD. Thus, with regards to non-postmenopausal subjects with osteoporosis or decreased BMD, outcomes remain inconclusive till the availability of adequate data in future trials.

Conclusion

In individuals with osteoporosis, especially postmenopausal women with osteoporosis or decreased BMD, ibandronate therapy has been found more effective in more serious conditions and when applied for longer durations. In particular, longer treatment duration from 1 to 5 years, increasing age, lower baseline T score, lower body weight, and higher baseline serum CTX levels predicted better efficacy of ibandronate. Lower baseline vitamin D levels and higher
serum BSAP levels predicted higher efficacy of ibandronate for lumbar spine but not for total hip.

**Author Contributions**

Conceived and designed the experiments: ZM YL MZ. Performed the experiments: ZM YL MZ KH. Analyzed the data: ZM HJH. Contributed reagents/materials/analysis tools: XPL XSX. Wrote the paper: ZM.

**References**

1. Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement 2000 March 27–29; 17 (1): 1–36. PMID: 11525451
2. International Osteoporosis Foundation. Facts and statistics. 2015. http://www.iofbonehealth.org/facts-statistics#category-21
3. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997; 7: 407–413. PMID: 9425497
4. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007; 22 (3): 465–475. PMID: 17144789
5. Orwell ES, Klein RF. Osteoporosis in men. Endocr Rev. 1995; 16: 87–116. PMID: 7758434
6. Magaziner J, Lydick E, Hawkes W, Zimmerman SI, Fox KM, Dolan M, et al. Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health.1997; 87:1630–1636. PMID: 9357344
7. Jette AM, Harris BA, Cleary PD, Campion EW. Functional recovery after hip fracture. Arch Phys Med Rehabil. 1987; 68(10): 735–40. PMID: 3662784
8. Magaziner J, Hawkes W, Hebel JR, Zimmerman SI, Fox KM, Dolan M, et al. Recovery from hip fracture in eight areas of function. J Gerontol Med Sci.2000; 55A: M498–M507.
9. Guggenbuhl P. Osteoporosis in males and females: Is there really a difference? Joint Bone Spine. 2009; 76: 595–601. doi: 10.1016/j.jbspin.2009.10.001 PMID: 19926512
10. McClung M, Harris ST, Paul D, Bauer DC, Davison KS, Dian L, et al. Bisphosphonate therapy for osteoporosis: Benefits, risks, and drug holiday. Am J Med. 2013; 126: 13–20. doi: 10.1016/j.amjmed.2012.06.025 PMID: 23177553
11. Borromeo GL, Tsao CE, Darby IB, Ebeling PR. A review of the clinical implications of bisphosphonates in dentistry. Aust Dent J. 2011; 56(1): 2–9. doi: 10.1111/j.1834-7819.2010.01283.x PMID: 21332734
12. Lazarovic TS, Mesilaty-Gross S, Vered I, Pariente C, Kanety H, Givol N, et al. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg. 2010; 68(9): 2241–2247. doi: 10.1016/j.joms.2010.05.043 PMID: 20728033
13. Rakel A, Boucher A, Ste-Marie LG. Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging. 2011; 6: 89–99. doi: 10.2147/CIA.S7282 PMID: 21594000
14. Adams S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone. 2004; 34(5): 881–889. PMID: 15121020
15. Anagnostis P, Vyzantiadis TA, Charizopoulou M, Adamidou F, Karras S, Goulis DG, et al. The effect of monthly ibandronate on BMD and bone turnover markers in patients with haemophilia A and B and increased risk for fracture. Thromb Haemost. 2013; 110(2): 257–263. doi: 10.1160/TH13-01-0030 PMID: 23740140
16. Bock O, Bösrt H, Beller G, Armbrecht G, Degner C, Martus P, et al. Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT. Bone. 2012; 50(1): 317–324. doi: 10.1016/j.bone.2011.02.027 PMID: 22067902
17. Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiesth A, et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19(6): 1241–1249. PMID: 15231010
18. Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC, Papapoulos SE. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone. 2005; 37(5): 651–654. PMID: 16126016
19. Recker RR, Weinstein RS, Chesnut CH 3rd, Schimmer RC, Mahoney P, Hughes C, et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int. 2004; 15(3): 231–237. PMID: 14727011

20. Cooper C, Emkey RD, McDonald RH, Hawker G, Bianchi G, Wilson K, et al. Efficacy and safety of weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003; 88(10): 4609–4615. PMID: 14557430

21. Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporos Int. 2012; 23(6): 1769–1778. doi: 10.1007/s00198-011-1793-9 PMID: 21975558

22. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, et al. Intravenous ibandronate or zoledronic acid in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006; 54(6): 1838–1846. PMID: 16729277

23. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal women: two-year results from the DIVA study. J Rheumatol. 2008; 35(3): 488–497. PMID: 18260172

24. Recker RR, Ste-Marie LG, Langdahl B, Czerwinski E, Bonvoisin B, Masanauskaite D, et al. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone. 2010; 46(3): 660–665. doi: 10.1016/j.bone.2009.11.004 PMID: 19909829

25. Miller PD, Recker RR, Harris S, Silverman S, Felsenberg D, Reginster J, et al. Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int. 2014; 25(1):349–357. doi: 10.1007/s00198-013-2517-0 PMID: 24160103

26. Pasalic KS; ESTHER Study Group. Efficacy and safety of once-monthly ibandronate treatment in patients with low BMD-ESTHER Study: 24 months of follow-up. Srp Arh Celok Lek. 2012; 140(11–12): 722–727. PMID: 23350245

27. Gonnelli S, Caffarelli C, Tanzilli L, Pondrelli C, Lucani B, Franci BM, et al. Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Bone. 2014; 61: 27–32. doi: 10.1016/j.bone.2013.12.017 PMID: 24389416

28. Guanabens N, Monegal A, Cerda D, Muxi A, Peris P, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology. 2013; 58(6): 2070–2078. doi: 10.1002/hep.26466 PMID: 23686738

29. Hakala M, Kroger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M, Heikkinen J, et al. Once-monthly oral ibandronate provides significant improvement in BMD in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial. Scand J Rheumatol. 2012; 41(4): 260–266. doi: 10.3109/03009742.2012.664447 PMID: 22803668

30. Kaemmerer D, Schmidt B, Lehmann G, Wolf G, Hommann M, Settmacher U. Monthly ibandronate for the prevention of bone loss in patients after liver transplantation. Transplant Proc. 2012; 44(5): 1362–1367. doi: 10.1016/transpro.2012.01.133 PMID: 22664016

31. Klaus J, Reinshagen M, Herdt K, Adler G, von Boyen GB, von Tirpitz C. Intravenous ibandronate or sodium-fluoride—a 3.5 years study on bone density and fractures in Crohn’s disease patients with osteoporosis. J Gastrointestin Liver Dis. 2011; 20(2): 141–148. PMID: 21725510

32. Li EK, Zhu TY, Hung VY, Kwok AW, Lee VW, Lee KK, et al. Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. Arthritis Res Ther. 2010; 12(5): R198. doi: 10.1186/ar3170 PMID: 20964867

33. Li M, Xing XP, Zhang ZL, Liu JL, Zhang ZL, Liu DG, et al. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases BMD in Chinese postmenopausal osteoporotic women: a 1-year study. J Bone Miner Metab. 2010; 28(3): 299–305. doi: 10.1007/s00774-009-0126-y PMID: 19855926

34. McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH 3rd, Ensrud KE, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res. 2004; 19(1): 11–8. PMID: 14753731

35. McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. Bone. 2009; 44(3): 418–422. doi: 10.1016/j.bone.2008.09.011 PMID: 18950736

36. Mitsopoulos E, Ginikopoulos J, Economidou D, Zanos S, Pateinakis P, Minasidis E, et al. Impact of long-term cinacalcet, ibandronate or teriparatide therapy on BMD of hemodialysis patients: a pilot study. Am J Nephrol. 2012; 36(3): 238–244. PMID: 22948280
37. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005; 20(8): 1315–1322. PMID: 16007327

38. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006; 65(5): 654–661. PMID: 16393289

39. Stakkestad JA, Lakatos P, Lorenc R, Sedarati F, Neate C, Reginster JY. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol. 2008; 27 (8): 955–960. doi: 10.1007/s10067-007-0824-6 PMID: 18180976

40. Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Clin Ther. 2009; 31(4): 751–761. doi: 10.1016/j.clinthera.2009.04.018 PMID: 19446148

41. Miller PD, Epstein S, Sedarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin. 2008; 24(1): 207–213. PMID: 18042311

42. Hagino H, Yoshida S, Hashimoto J, Matsunaga M, Tobinai M, Nakamura T. Increased BMD with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study. Calcif Tissue Int. 2014; 95(6): 557–563. doi: 10.1007/s00223-014-9927-7 PMID: 25377907

43. Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, et al. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int. 2013; 93(2): 137–146. doi: 10.1007/s00223-013-9734-6 PMID: 23644930

44. Ravn P, Clemmesen B, Riis BJ, Christiansen S. The Effect on Bone Mass and Bone Markers of Different Doses of Ibandronate: A New Bisphosphonate for Prevention and Treatment of Postmenopausal Osteoporosis: A 1-Year, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study. Bone. 1996; 19(5): 527–533. PMID: 8922653

45. Recker R, Stakkestad JA, Chesnut CH 3rd, Christiansen C, Skag A, Hoiseth A, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone. 2004; 34(5): 890–899. PMID: 15121021

46. Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013; 121(6): 1291–1299. doi: 10.1097/AOG.0b013e318291718c PMID: 23812464

47. Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res. 2001; 16(10): 1871–1878. PMID: 11585352

48. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int. 2003a; 14(10): 801–807.

49. Ringe JD, Dorst A, Faber H, Ibach K, Preuss J. Three-monthly intravenous ibandronate injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatol (Oxford). 2003b; 42(6): 743–749.

50. Senn C, Günther B, Popp AW, Perrelet R, Hans D, Lippuner K. Comparative effects of teriparatide and ibandronate on spine BMD (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int. 2014; 25(7): 1945–1951. doi: 10.1007/s00198-014-2703-8 PMID: 24760244

51. Smerud KT, Dolgos S, Olsen IC, Asberg A, Sagdal S, Reisaeter AV, et al. A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation. Am J Transplant. 2012; 12(12): 3316–3325. doi: 10.1111/j.1600-6143.2012.04233.x PMID: 22946930

52. Genant HK, Lewiecki EM, Fuerst T, Fries M. Effect of monthly ibandronate on hip structural geometry in men with low bone density. Osteoporos Int. 2012; 23(1): 257–265. doi: 10.1007/s00198-011-1732-9 PMID: 21811866

53. Orwell ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G. Efficacy and safety of monthly ibandronate in men with low bone density. Bone. 2010; 46(4): 970–976. doi: 10.1016/j.bone.2009.12.034 PMID: 20060082

54. Tanko LB, Felsenberg D, Czerwinski E, Burdeska A, Jonkanski I, Hughes C, et al. Oral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med. 2003a; 254(2): 159–167.
55. Tanko LB, McClung MR, Schimrer RC, Mahoney P, Christiansen C. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. Bone. 2003; 32(4): 421–426. PMID: 12689686

56. Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med. 1997; 103 (4): 298–307. PMID: 9382122

57. Misof BM, Patsch JM, Roschger P, Muschitz C, Gamsjaeger S, Paschalis EP, et al. Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study. J Bone Miner Res. 2014; 29(2): 440–449. doi: 10.1002/jbmr.2035 PMID: 23832525

58. Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2014; 25(12): 2729–2741. doi: 10.1007/s00198-014-2817-2 PMID: 25074351

59. Sebba AI, Emkey RD, Kohles JD, Sambrook PN. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone. 2009; 44(3): 423–7. doi: 10.1016/j.bone.2008.10.052 PMID: 19049913

60. Hou Y, Gu K, Xu C, Ding H, Liu C, Tuoheti Y. Dose-effectiveness relationships determining the efficacy of ibandronate for management of osteoporosis: A meta-analysis. Medicine (Baltimore). 2015; 94(26): e1007. doi: 10.1097/MD.0000000000001007

61. Mandema JW, Zheng J, Libanati C, Perez Ruixo JJ. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. J Clin Endocrinol Metab. 2014; 99(10): 3746–3755. doi: 10.1210/jc.2013-3795 PMID: 24915115

62. Asche C, Nelson R, McAdam-Marx C, Jhaveri M, Ye X. Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. Osteoporos Int. 2010; 21(8): 1427–1436. doi: 10.1007/s00198-009-1079-7 PMID: 19794549

63. Brennan RM, Wactawski-Wende J, Crespo CJ, Dmochowski J. Factors associated with treatment initiation after osteoporosis screening. Am J Epidemiol. 2004; 160(5): 475–483. PMID: 15321845

64. Cranney A, Tsang JF, Leslie WD. Factors predicting osteoporosis treatment initiation in a regionally based cohort. Osteoporos Int. 2008; 20(9): 1621–1625. doi: 10.1007/s00198-008-0823-8 PMID: 19096744

65. Phillipov G, Mos E, Scinto S, Phillips PJ. Initiation of hormone replacement therapy after diagnosis of osteoporosis by bone densitometry. Osteoporos Int. 1997; 7(2): 162–164. PMID: 9166398

66. Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am. 2000; 82(8): 1063–1070. PMID: 10954094

67. Rozental TD, Makhni EC, Day CS, Bouxsein ML. Improving evaluation and treatment for osteoporosis in older adults. Osteoporos Int. 2009; 20(11): 1963–1967. doi: 10.1007/s00198-008-0831-8 PMID: 19151910

68. Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995; 17(Suppl): 505S–511S. PMID: 8573428

69. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, et al. Identification and fracture outcomes of undiagnosed low BMD in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001; 286(22): 2815–2822. PMID: 11735756

70. Nayak S, Roberts MS, Greenspan SL. Factors associated with diagnosis and treatment of osteoporosis in older adults. Osteoporos Int. 2009; 20(11): 1963–1967. doi: 10.1007/s00198-008-0831-8 PMID: 19151910

71. Pasoff M. C-terminal cross-linking telopeptide as a serological marker for bisphosphonate-related osteonecrosis of the jaw: review of 2 cases. J Can Dent Assoc. 2013; 79(d51. PMID: 23920073

72. Bouchard C, Fortin M. CTX as a marker for BRONJ. J Can Dent Assoc. 2013; 79:d173. PMID: 24309053

73. Rossini M, Orsolini G, Adami S, Kunnathully V, Gatti D. Osteoporosis treatment: why ibandronic acid? Expert Opin Pharmacother. 2013; 14(10): 1371–1381. doi: 10.1517/14656566.2013.795949 PMID: 23650954

74. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in post-menopausal US women with acute hip fracture. JAMA. 1999; 281: 1505–1511. PMID: 10227320

75. LeBoff MS, Hawkies WG, Glowacki J, Yu-Yahiro J, Hurwitz S, Magaziner J. Vitamin D-deficiency and post-fracture changes in lower extremity function and falls in women with hip fractures. Osteoporos Int. 2008; 19(9): 1283–90. doi: 10.1007/s00198-008-0582-6 PMID: 18373057
76. Pieper CF, Colon-Emeric C, Caminis J, Betchyk K, Zhang J, Janning C, et al. Distribution and correlates of serum 25-hydroxyvitamin D levels in a sample of patients with hip fracture. Am J Geriatr Pharmacother. 2007; 5: 335–340. doi: 10.1016/j.amjpharm.2007.12.004 PMID: 18179991

77. Zhu K, Devine A, Dick IM, Wilson SG, Prince RL. Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. J Clin Endocrinol Metab. 2008; 93(3): 743–749. PMID: 18089701

78. Avenell A, Mak JC, O’Connell D. Vitamin D and vitamin D analogues for preventing fractures in postmenopausal women and older men. Cochrane Database Syst Rev. 2014; 4: CD000227. doi: 10.1002/14651858.CD000227.pub4 PMID: 24729336

79. De Laet C, Kanis JA, Odén A, Johanson H, Johnell O, Delmas P, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005; 16(11): 1330–1338. PMID: 15928804

80. Fawzy T, Muttapallaymyalil J, Sreedharan J, Ahmed A, Alshamsi SO, Al Ali MS, et al. Association between body mass index and bone mineral density in patients referred for dual-energy x-ray absorptiometry scan in Ajman, UAE. J Osteoporos. 2011; 2011: 876309. doi: 10.4061/2011/876309 PMID: 21772978